



SoonerSelect Medical Contracted Entity (CE) Requests to Change Service Provisions

The SoonerSelect Medical Contract at Section 1.7: Covered Benefits and Section 1.8: Medical Management states that medical contracted entities (CEs) may not impose prior authorization guidelines/criteria or utilization management practices that are more restrictive than OHCA without OHCA prior approval.

On May 12, 2025, Humana Healthy Horizons of Oklahoma submitted a formal request to OHCA for review and approval to change service provisions.

OHCA subject matter experts (SMEs) reviewed the requests, evaluating them in comparison to OHCA historical processes and practices, standard business practice in other markets, and available data to determine whether to approve the requests.

OHCA decisions are noted in the table below:

SoonerSelect Medical Requests to Change Service Provisions				
PROCEDURE CODE(S) IMPACTED	OHCA'S CURRENT CLAIMS PROCESSING PROTOCOL	PROPOSED MODIFICATION TO CLAIMS PROCESSING PROTOCOL	ANTICIPATED IMPACT	OHCA DECISION
Implementation of PA Requirement				
Prior authorize CPT Code 38999 for new gene cell therapy Tecelra.	OHCA has a pharmacy coverage policy for this therapy, which states a PA code is required.	Humana will require prior authorization for the procedure code listed and will ensure any request for this service is reviewed for medical necessity.	Humana expects for requests for this CPT code to be extremely rare, as Humana does not have any current requests for this code, nor any requests for this therapy to date.	Approved for dates of service on or after June 2, 2025